Search Results for: malignancies

March 19, 2025March 19, 2025

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies.

Melanoma Literature

Publication date: Mar 18, 2025 Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of patients with relapsed/refractory (R/R) hematologic malignancies, including B-cell lymphomas and multiple myeloma (MM). While ... Read more

March 19, 2025March 19, 2025

The correlation of clinical and histopathological features of eyelid malignancies: a 5-year retrospective study in Vietnam.

Melanoma Literature

Publication date: Mar 18, 2025 To analyze the correlation between the clinical and histopathological features of eyelid malignancies in Vietnam. An observational retrospective study was conducted on 190 patients who ... Read more

March 13, 2025March 13, 2025

Somatic Malignancies Arising in Ovarian Mature Cystic Teratomas: A Multi-Institutional Study of 40 Cases Highlighting Outcomes and Novel Malignancies.

Melanoma Literature

Publication date: Mar 12, 2025 Somatic malignancy arising in ovarian mature cystic teratoma (MCT) is a relatively rare phenomenon with an estimated incidence ranging from 0. 17% to 5. 5%. ... Read more

March 12, 2025March 12, 2025

An Open-Label Phase 1 Study to Evaluate PF-08046032 as Monotherapy and Part of Combination Therapy in Participants With Advanced Malignancies.

Melanoma News

Publication date: Mar 05, 2025 The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with ... Read more

March 4, 2025March 4, 2025

Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022.

Melanoma Literature

Publication date: Mar 03, 2025 Despite high response rates, anti-PD-1 therapy monotherapy eventually fails in most patients with relapsed or refractory Hodgkin Lymphoma (HL) and is generally ineffective in most ... Read more

March 1, 2025March 1, 2025

Effect of Secondary Infections on the Outcomes of Patients with Hematological Malignancies and SARS-CoV-2 Infection: Results from the HM-COV 3.0 Study.

Coronavirus Literature

Publication date: Feb 16, 2025 Patients with hematological malignancies (HMs) are at higher risk of severe COVID-19 and secondary infections, which further complicate their outcomes. This study evaluated the impact ... Read more

March 1, 2025March 1, 2025

Effect of Secondary Infections on the Outcomes of Patients with Hematological Malignancies and SARS-CoV-2 Infection: Results from the HM-COV 3.0 Study.

Coronavirus Literature

March 1, 2025March 1, 2025

Effect of Secondary Infections on the Outcomes of Patients with Hematological Malignancies and SARS-CoV-2 Infection: Results from the HM-COV 3.0 Study.

Coronavirus Literature

March 1, 2025March 1, 2025

Effect of Secondary Infections on the Outcomes of Patients with Hematological Malignancies and SARS-CoV-2 Infection: Results from the HM-COV 3.0 Study.

Coronavirus Literature

March 1, 2025March 1, 2025

Effect of Secondary Infections on the Outcomes of Patients with Hematological Malignancies and SARS-CoV-2 Infection: Results from the HM-COV 3.0 Study.

Coronavirus Literature